KR20200019220A - 외상성 뇌 손상 및 이의 후유증에 대한 에피샤페롬 저해제 치료법 - Google Patents

외상성 뇌 손상 및 이의 후유증에 대한 에피샤페롬 저해제 치료법 Download PDF

Info

Publication number
KR20200019220A
KR20200019220A KR1020207001656A KR20207001656A KR20200019220A KR 20200019220 A KR20200019220 A KR 20200019220A KR 1020207001656 A KR1020207001656 A KR 1020207001656A KR 20207001656 A KR20207001656 A KR 20207001656A KR 20200019220 A KR20200019220 A KR 20200019220A
Authority
KR
South Korea
Prior art keywords
bbb
permeable
epichaperom
inhibitor
tbi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020207001656A
Other languages
English (en)
Korean (ko)
Inventor
바바라 피. 월너
Original Assignee
사무스 테라퓨틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사무스 테라퓨틱스, 인코포레이티드 filed Critical 사무스 테라퓨틱스, 인코포레이티드
Publication of KR20200019220A publication Critical patent/KR20200019220A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F17/00—First-aid kits
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Physiology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020207001656A 2017-06-23 2018-06-22 외상성 뇌 손상 및 이의 후유증에 대한 에피샤페롬 저해제 치료법 Withdrawn KR20200019220A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762524452P 2017-06-23 2017-06-23
US62/524,452 2017-06-23
US201762532989P 2017-07-14 2017-07-14
US62/532,989 2017-07-14
PCT/US2018/038893 WO2018237211A2 (en) 2017-06-23 2018-06-22 Epichaperome inhibitor therapy for traumatic brain injury and sequelae thereof

Publications (1)

Publication Number Publication Date
KR20200019220A true KR20200019220A (ko) 2020-02-21

Family

ID=64737388

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207001656A Withdrawn KR20200019220A (ko) 2017-06-23 2018-06-22 외상성 뇌 손상 및 이의 후유증에 대한 에피샤페롬 저해제 치료법

Country Status (10)

Country Link
US (1) US20210161902A1 (https=)
EP (1) EP3641751A4 (https=)
JP (1) JP2020525451A (https=)
KR (1) KR20200019220A (https=)
CN (1) CN111683658A (https=)
AU (1) AU2018290288A1 (https=)
CA (1) CA3068274A1 (https=)
IL (1) IL271387A (https=)
TW (1) TW201919613A (https=)
WO (1) WO2018237211A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913562VA (en) * 2017-04-24 2020-03-30 Samus Therapeutics Inc Hsp90 inhibitor oral formulations and related methods
WO2023097071A2 (en) * 2021-11-29 2023-06-01 The Regents Of The University Of California Methods for treating traumatic brain injury

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10336757B2 (en) * 2006-06-30 2019-07-02 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases through inhibition of HSP90
WO2011044394A1 (en) * 2009-10-07 2011-04-14 Sloan-Kettering Institute For Cancer Research Purine derivatives useful as hsp90 inhibitors
US20110201587A1 (en) * 2010-02-16 2011-08-18 Bio Holding, Inc. Hsp90 inhibitors and methods of use
WO2012138894A1 (en) * 2011-04-05 2012-10-11 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
SG10201913562VA (en) * 2017-04-24 2020-03-30 Samus Therapeutics Inc Hsp90 inhibitor oral formulations and related methods

Also Published As

Publication number Publication date
US20210161902A1 (en) 2021-06-03
JP2020525451A (ja) 2020-08-27
EP3641751A2 (en) 2020-04-29
AU2018290288A1 (en) 2020-01-16
EP3641751A4 (en) 2021-03-31
TW201919613A (zh) 2019-06-01
WO2018237211A3 (en) 2019-03-14
CN111683658A (zh) 2020-09-18
CA3068274A1 (en) 2018-12-27
IL271387A (en) 2020-01-30
WO2018237211A2 (en) 2018-12-27

Similar Documents

Publication Publication Date Title
ES2957159T3 (es) Estimuladores de SGC fusionados bicíclicos
EP2916868B1 (en) Pharmaceutical compositions containing a pde4 inhibitor and a pi3 delta or dual pi3 delta-gamma kinase inhibitor
US20110269777A1 (en) Methods and compositions for treating schizophrenia using antipsychotic combination therapy
JP7150740B2 (ja) ｓＧＣ刺激薬による中枢神経系疾患の治療
KR20190065265A (ko) 리실 옥시다제 유사 2 억제제의 용도
ES2969532T3 (es) 3-(4-((4-(Morfolinometil-bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona para el tratamiento de lupus eritematoso sistémico
JP2022130689A (ja) Ｓｇｃ刺激剤の固体形態
JP2017501140A (ja) 同種抗体により駆動される慢性移植片対宿主病を処置及び予防する方法
KR20180104123A (ko) 비알콜성 지방간염 (NASH)의 치료를 위한 sGC 자극제의 용도
US20230098667A1 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US20190298740A1 (en) Methods and compositions for treating hallucinations and conditions related to the same
KR20200019220A (ko) 외상성 뇌 손상 및 이의 후유증에 대한 에피샤페롬 저해제 치료법
KR20100038120A (ko) 신경퇴행성 장애의 치료를 위한 신규한 네라멕산 조합물
JP6889493B2 (ja) 脳卒中からの回復のための方法および組成物
JP7007559B2 (ja) 白内障の予防剤および治療剤、並びに、これらを製造するための、ｄｎａ損傷に応答するシグナル伝達経路を阻害する阻害剤の使用
US20230390223A1 (en) Administration of antipurinergic compositions for treating nervous system disorders
JP2018516990A (ja) シスチン・グルタミン酸トランスポーター阻害剤の新規な使用の方法
JP2022502441A (ja) Ｃｃｒ３阻害剤を用いて、加齢性機能障害を治療するための方法および組成物
CN111346093B (zh) 拉米夫定、多潘立酮联合用于制备镇静药物的应用
CN104473932A (zh) 治疗中枢神经系统炎症性脱髓鞘疾病的药物组合物及其联合给药的用途
WO2023107428A1 (en) Methods for treating traumatic brain injury
RU2508096C2 (ru) Способы и композиции для лечения шизофрении с использованием нейролептической комбинированной терапии
WO2018106118A1 (en) Treatment of diffuse intrinsic pontine glioma
EA041012B1 (ru) ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ С ПОМОЩЬЮ СТИМУЛЯТОРОВ sGC

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200117

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210622

Comment text: Request for Examination of Application

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20230320

WITB Written withdrawal of application